0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Neurology |

This Month in Archives of Neurology FREE

Arch Neurol. 2010;67(4):382-384. doi:10.1001/archneurol.2010.26.
Text Size: A A A
Published online

CLEARANCE OF MUTANT PROTEINS AS A THERAPEUTIC TARGET IN NEURODEGENERATIVE DISEASES

KraincArticle emphasizes that accumulation and aggregation of disease-causing proteins is a hallmark of several neurodegenerative disorders such as Parkinson, Alzheimer, and Huntington diseases. One of the main goals of research in neurodegenerative disorders has been to improve clearance of these accumulated proteins. Using the example of Huntington disease, he discusses strategies to selectively activate cellular degradation machinery to improve clearance of the mutant protein and identify therapeutic targets for the treatment of Huntington disease and related neurodegenerative disorders.

CONNECTING GENES TO BRAIN IN THE AUTISM SPECTRUM DISORDERS

Abrahams and GeschwindArticle indicate that the autism spectrum disorders are a complex group of neuropsychiatric conditions that involve language, social communication, and mental flexibility. Here, they attempt to place recent genetic advances in a developmental and anatomical context. Recent progress in identifying autism spectrum disorder candidate genes supports the involvement of multiple brain regions including the frontal lobes, anterior temporal lobes, caudate, and cerebellum. Understanding genetic data in an anatomical context will be critical to explain how individual risk factors operate to shape phenotypic presentation in patients.

MULTIPLE SCLEROSIS: CLINICAL EFFECT OF NEUTRALIZING ANTIBODIES TO INTERFERON BETA THAT PERSIST LONG AFTER CESSATION OF THERAPY

In their study van der Voort and colleaguesArticle report that anti–interferon beta–neutralizing antibodies can persist after interferon beta therapy withdrawal and are associated with overt clinical disease activity. This is made apparent by an increase in relapse rate and faster disability progression and supported by the observed need for more aggressive therapy after interferon beta therapy cessation. Editorial perspective is provided by J. T. Phillips, MD, PhD.Article

COMPARATIVE EFFECTIVENESS OF 10 ANTIEPILEPTIC DRUGS IN OLDER ADULTS WITH EPILEPSY

Arif et alArticle compared the effectiveness of antiepileptic drugs for use in older adults with epilepsy. Lamotrigine was the most effective antiepileptic drug, as measured by 12-month retention and seizure freedom, with levetiracetam a close second. Oxcarbazepine was consistently less effective than most other antiepileptic drugs.

Place holder to copy figure label and caption

Twelve-month retention rate in older adults with epilepsy newly started on an antiepileptic drug (AED) regimen (includes all AEDs taken by at least 10 patients) (overall, n = 247 patients; 436 patient-drug combinations). CBZ indicates carbamazepine; CLB, clobazam; GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PHT, phenytoin; TPM, topiramate; VPA, valproate sodium; and ZNS, zonisamide.

Graphic Jump Location

SEROTONIN 2A RECEPTORS AND VISUAL HALLUCINATIONS IN PARKINSON DISEASE

Ballanger and colleaguesArticle report with this pilot study the first in vivo evidence that suggests a role for serotonin 2A receptors in mediating visual hallucinations via the ventral visual stream in Parkinson disease. This imaging study provides a rational basis for treatment studies using selective serotonin 2A receptor antagonists, which has important implications for the clinical management of visual hallucinations and psychosis in Parkinson disease.

SYNTAXIN 1A INVOLVEMENT IN MIGRAINE SUSCEPTIBILITY

Lemos et alArticle confirm the involvement of syntaxin 1A in migraine susceptibility regarding the single-nucleotide polymorphism rs941298. In addition, they found rs6951030 to also be associated in Portuguese patients with migraine. Sex differences need to be explored to disentangle possible sex susceptibility in syntaxin 1A.

LEAN MASS IS REDUCED IN EARLY ALZHEIMER DISEASE

Burns and colleaguesArticle report that loss of lean mass is accelerated in Alzheimer disease and is associated with brain atrophy and cognitive performance, perhaps as a direct or indirect consequence of Alzheimer disease pathophysiology or through shared mechanisms common to both Alzheimer disease and sarcopenia.

CEREBROVASCULAR CARBON DIOXIDE REACTIVITY AND DELAYED CEREBRAL ISCHEMIA AFTER SUBARACHNOID HEMORRHAGE

Carrera and colleaguesArticle determined the predictors of impaired cerebrovascular reactivity (CVR) and the value of CVR to predict delayed cerebral ischemia. They found that impaired CVR in response to carbon dioxide challenge is frequent after subarachnoid hemorrhage, particularly in patients with poor clinical grade. Progressive loss of normal CVR identifies patients at high risk of delayed cerebral ischemia, and persistently normal reactivity implies low risk.

COMPARABLE RESULTS OF FDG-PET CEREBRAL GLUCOSE UPTAKE AND DTBZ-PET CEREBRAL BLOOD FLOW IN EVALUATION OF EARLY DEMENTIA AND MILD COGNITIVE IMPAIRMENT

Albin and colleaguesArticle compared assessment of regional cerebral metabolic changes with [11C]dihydrotetrabenazine–positron-emission tomography (DTBZ-PET) measurement of regional cerebral blood flow (K1) and fludeoxyglucose F18 (FDG)–PET measurement of regional cerebral glucose uptake (CMRglc) in a clinically representative sample of subjects with mild dementia and mild cognitive impairment (MCI). They hypothesized that DTBZ-PET K1 and FDG-PET CMRglc provide equivalent information. They report that DTBZ-PET K1 and FDG-PET CMRglc provide comparable information in assessment of regional cerebral metabolic deficits in mild dementia and MCI. Measures of K1 can assess regional cerebral metabolism deficits accurately in mild dementia and MCI; K1 assessments of regional cerebral metabolic deficits can be combined with tracer binding results to improve utility of PET imaging in mild dementia and MCI.

RELATIONSHIP OF CORTICAL ATROPHY TO FATIGUE IN PATIENTS WITH MULTIPLE SCLEROSIS

Pellicano et alArticle investigated the relationship between fatigue in multiple sclerosis and regional cortical and subcortical gray matter atrophy. They report that cortical atrophy of the parietal lobe had the strongest relationship with fatigue. Given the implications of the posterior parietal cortex in motor planning and integration of information from different sources, the interpretation of their preliminary results is that dysfunctions in higher-order aspects of motor control may have a role in determining fatigue in multiple sclerosis.

NOVEL FUS/TLS MUTATIONS AND PATHOLOGY IN FAMILIAL AND SPORADIC AMYOTROPHIC LATERAL SCLEROSIS

Hewitt and colleaguesArticle indicate that mutations in FUS/TLS have recently been found to cosegregate with familial cases of amyotrophic lateral sclerosis (ALS). The aim of the present study was to determine the frequency of and clinicopathological phenotypes associated with FUS/TLS mutations in a large cohort of ALS cases. They find that FUS/TLS mutations represented approximately 5% of familial ALS cases screened. A FUS/TLS mutation was also identified in a single sporadic ALS case. Subsequent screening of this region in a larger cohort of sporadic ALS cases, however, did not reveal any additional mutations.

HYPOMETABOLISM IN ALZHEIMER DISEASE–AFFECTED BRAIN REGIONS IN COGNITIVELY HEALTHY LATINO INDIVIDUALS WHO CARRY THE APOLIPOPROTEIN E Ε4 ALLELE

Langbaum et alArticle studied the extent to which the apolipoprotein E (APOE) ε4 allele is a susceptibility gene for late-onset Alzheimer disease (AD) in Latino individuals. Fluorodeoxyglucose positron emission tomography (FDG-PET) was used to investigate whether regional reductions in the cerebral metabolic rate for glucose previously found in cognitively healthy late-middle-aged APOE ε4 carriers extends to members of the Latino Mexican American community. They obtained support for the relationship between APOE ε4 and risk of AD in Latino individuals. It illustrates the role of PET as a presymptomatic endophenotype for the assessment of AD risk factors and supports the inclusion of Latino APOE ε4 carriers in proof-of-concept studies that use FDG-PET to evaluate promising presymptomatic treatments in cognitively healthy carriers of this common AD susceptibility gene.

DISORGANIZED SENSORIMOTOR INTEGRATION IN MUTATION-POSITIVE MYOCLONUS-DYSTONIA: A FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDY

Beukers et alArticle report that in SGCE mutation carriers, significant hyperresponsiveness in contralateral inferior parietal cortical areas, ipsilateral premotor and primary somatosensory cortex, and ipsilateral cerebellum were observed during the motor task compared with healthy controls. The cortical activation patterns in SGCE mutation carriers during this motor task point to disorganized sensorimotor integration in this uniform group of dystonic patients and are consistent with functional neuroimaging studies in other types of (hereditary) dystonia.

ASSOCIATION OF MAGNETIC RESONANCE IMAGING MEASURES WITH COGNITIVE FUNCTION IN A BIRACIAL POPULATION SAMPLE

Aggarwal and colleaguesArticle review that white matter hyperintensity volume, cerebral infarcts, and total brain volume are associated with cognitive function but that few studies have examined these associations in the general population or whether they differ by race. The authors examined the association of white matter hyperintensity volume, cerebral infarcts, and total brain volume with global cognition and cognition in 5 separate domains in a biracial population sample. They report that the associations of magnetic resonance imaging measures with cognition differed according to subjects' clinical status (stronger among subjects without dementia) and were not modified by race. These associations did not affect all cognitive domains equally but were more consistent with impairments in perceptual speed.

WHAT IS SEMANTIC DEMENTIA?

Kertesz et alArticle describe a large, clinically defined cohort of patients with semantic dementia, highlighting important, sometimes overlooked features and comparing it with similar entities. They indicate that semantic dementia is distinguishable from other presentations of frontotemporal dementia and Alzheimer disease, not only by fluent speech and impaired comprehension without loss of episodic memory, syntax, and phonology but also by empty, garrulous speech with thematic perseverations, semantic paraphasias, and poor category fluency. Questioning the meaning of words is an important diagnostic clue not seen in other groups, and behavior change is prevalent.

Figures

Place holder to copy figure label and caption

Twelve-month retention rate in older adults with epilepsy newly started on an antiepileptic drug (AED) regimen (includes all AEDs taken by at least 10 patients) (overall, n = 247 patients; 436 patient-drug combinations). CBZ indicates carbamazepine; CLB, clobazam; GBP, gabapentin; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PHT, phenytoin; TPM, topiramate; VPA, valproate sodium; and ZNS, zonisamide.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

259 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs